Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan:162:105458.
doi: 10.1016/j.neuint.2022.105458. Epub 2022 Nov 30.

Stroke: Molecular mechanisms and therapies: Update on recent developments

Affiliations
Review

Stroke: Molecular mechanisms and therapies: Update on recent developments

Faheem Shehjar et al. Neurochem Int. 2023 Jan.

Abstract

Stroke, a neurological disease, is one of the leading causes of death worldwide, resulting in long-term disability in most survivors. Annual stroke costs in the United States alone were estimated at $46 billion recently. Stroke pathophysiology is complex, involving multiple causal factors, among which atherosclerosis, thrombus, and embolus are prevalent. The molecular mechanisms involved in the pathophysiology are essential to understanding targeted drug development. Some common mechanisms are excitotoxicity and calcium overload, oxidative stress, and neuroinflammation. In addition, various modifiable and non-modifiable risk factors increase the chances of stroke manifolds. Once a patient encounters a stroke, complete restoration of motor ability and cognitive skills is often rare. Therefore, shaping therapeutic strategies is paramount for finding a viable therapeutic agent. Apart from tPA, an FDA-approved therapy that is applied in most stroke cases, many other therapeutic strategies have been met with limited success. Stroke therapies often involve a combination of multiple strategies to restore the patient's normal function. Certain drugs like Gamma-aminobutyric receptor agonists (GABA), Glutamate Receptor inhibitors, Sodium, and Calcium channel blockers, and fibrinogen-depleting agents have shown promise in stroke treatment. Recently, a drug, DM199, a recombinant (synthetic) form of a naturally occurring protein called human tissue kallikrein-1 (KLK1), has shown great potential in treating stroke with fewer side effects. Furthermore, DM199 has been found to overcome the limitations presented when using tPA and/or mechanical thrombectomy. Cell-based therapies like Neural Stem Cells, Hematopoietic stem cells (HSCs), and Human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) are also being explored as a treatment of choice for stroke. These therapeutic agents come with merits and demerits, but continuous research and efforts are being made to develop the best therapeutic strategies to minimize the damage post-stroke and restore complete neurological function in stroke patients.

Keywords: Hemorrhagic; Ischemic; Pathophysiology; Risk factors; Stroke; Stroke therapeutics.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Pathophysiology of hemorrhagic & ischemic stroke: Excitoxicity, neuroinflammation, oxidative stress and angiopathy leading to cerebral damage and neuronal death.
Fig. 2.
Fig. 2.
Non-modifiable and modifiable risk factors which increase the chances of stroke.
Fig. 3.
Fig. 3.
Various types of therapies used for stroke treatment and recovery.

References

    1. Abdul Y, et al., 2019. Inhibition of Toll-Like Receptor-4 (TLR-4) Improves Neurobehavioral Outcomes After Acute Ischemic Stroke in Diabetic Rats: Possible Role of Vascular Endothelial TLR-4. Mol. Neurobiol. 56, 1607–1617. 10.1007/s12035-018-1184-8 - DOI - PMC - PubMed
    1. Alaqel SI, et al., 2022. Synthesis and Development of a Novel First-in-Class Cofilin Inhibitor for Neuroinflammation in Hemorrhagic Brain Injury. ACS Chem. Neurosci. 10.1021/acschemneuro.2c00010 - DOI - PMC - PubMed
    1. Alhadidi Q, et al., 2018. Cofilin Knockdown Attenuates Hemorrhagic Brain Injury-induced Oxidative Stress and Microglial Activation in Mice. Neuroscience 383, 33–45. 10.1016/j.neuroscience.2018.04.036 - DOI - PMC - PubMed
    1. Alkhaneen H, et al., 2022. Differences of Lipid Profile Among Ischemic and Hemorrhagic Stroke Patients in a Tertiary Hospital in Riyadh, Saudi Arabia: A Retrospective Cohort Study. Cureus 14. 10.7759/cureus.25540 - DOI - PMC - PubMed
    1. Andrabi SS, Parvez S, Tabassum H, 2020. Ischemic stroke and mitochondria: mechanisms and targets. Protoplasma 257, 335–343. 10.1007/s00709-019-01439-2 - DOI - PubMed

Publication types